Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy.

ABSTRACT:

Introduction

Two distinct molecular groups of HCC have been recently associated with a better response to atezolizumab-bevacizumab. One of these, "angiogenesis-driven," is related to HCC vascularization. Vessels that encapsulate tumor clusters (VETCs) is a morphological form of angiogenesis associated with worse prognosis in resected and transplanted HCC. The aim of this study was to explore if VETC can be used, at morphological level, to potentially surrogate the angiogenesis-driven molecular subgroup to identify HCC patients who might benefit of antiangiogenic treatments.

Methods

The significance of VETC was first explored in a retrospective, single institution series of 75 patients with unresectable HCC (study cohort) and later validated in an external, retrospective seri

SUBMITTER: De Carlo C 

PROVIDER: S-EPMC12721808 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature